News

Under the deal, LLR will provide access to new therapies currently being researched by its scientists, as well as offer financial support for Cancer Research UK to develop

MuGard is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. PlasmaTech Biopharmaceuticals

AKB-6548 is designed to stabilize hypoxia inducible factor (HIF), a transcription factor that regulates the expression of genes involved with red blood cell (RBC) production in response to

Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition. Kabiven was approved by the U.S. Food

This finding is the culmination of more than 10 years of work by more than a dozen scientists and clinicians in the research team in Sarasota. Alzheimer’s has

The U.S. Food and Drug Administration (FDA) has approved Octagam10% for the treatment of adults with chronic Immune Thrombocytopenic Purpura (ITP), a platelet disorder that can result in

Over the past seven months, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana’s

XTEN is Amunix’s proprietary protein-based polymer that mimics the biophysical properties of PEG and is used to extend the half-life of genetically fused therapeutic proteins and peptides. "We

Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The breakthrough status for Keytruda is to treat these patients